Medpace Holdings, Inc. — Diagnostics & Research. Scored on the same transparent 7-signal model behind the daily rankings.
★
MEDP
Medpace Holdings, Inc. · Diagnostics & Research
FCF$711mC+
Rev+24.2%A-
D/E0.24B
P/E33.9xC+
PEG3.27D
70.7Score
$538.23$15.4B
1Y Target$451.42Analyst consensus · 12 analysts
5Y Target$660.92Compound horizon
10Y Target$980.43Long-dated conviction
FCF$711mTTMC+
FCF $711m — respectable but not differentiating
Rev+24.2%TTM YoYA-
Revenue +24.2% — strong growth, well above S&P median (~7%)
D/E0.24B
D/E 0.24 — near the Healthcare debt median (≈60th pctile)
P/E33.9xC+
P/E 33.9 — above the Healthcare median (≈75th pctile)
PEG3.27D
PEG 3.27 — very expensive; pricing in best-case scenarios
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 70.7
Quality0.89
Growth0.98
Value0.41
Why this score
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week high
14% off the 12-month high
vs DCF fair value41% aboveest. fair value ~$381
What the price assumes: free cash flow compounding at ~16% a year for the next decade — vs the ~10% a year our model projects from current growth and analyst estimates.
Quality signals · context only
ROIC74.3% · Areturn on invested capital — not score-weighted
Why now
Diagnostics & Research · market cap $15.4b. 14% off the 52-week high of $628.92. Revenue growing +24%, comfortably above the S&P median. 12 sell-side analysts rate this a Hold with a mean 1-yr target of $451.42 (implying -16% upside).
Moat
Net margin 17% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 77% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 154% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 34x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Horizon
1-3 yr $451.42 (12-analyst consensus) — fundamentals + valuation re-rating. 5 yr $660.92 at ~4% CAGR — compounding case rests on the competitive position widening. 10 yr $980.43 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · MEDP
Trend
-3.3 over 15 daily scores
From 74.0 (Jun 22) → 70.7 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · MEDP
$
%
%
Shares to buy
3
Position size
$1,615
3.2% of portfolio
Stop price
$403.67
25% below $538.23
$ at risk if stopped
$403.67
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Medpace Holdings, Inc. (MEDP): score, valuation & FAQ
Medpace Holdings, Inc. (MEDP) is a Diagnostics & Research company that scores 70.7 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A-), while PEG (D) rate weaker. On valuation, MEDP sits about 41% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade.
Is MEDP a good stock to buy?
Bull Rankings scores MEDP 70.7 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by Rev (A-). A score is a quantitative screen of Medpace Holdings, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does MEDP score 70.7 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). MEDP earns its highest marks on Rev (A-), and is held back by PEG (D). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is MEDP overvalued or undervalued?
Based on $538.23, MEDP sits about 41% above our discounted-cash-flow fair value — the current price implies roughly 16% annual free-cash-flow growth over the next decade. It trades at a 33.9x× P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in MEDP?
Trailing P/E 34x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.